2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1487

Impact of TNF-α Inhibitor on Lipid Profile and Atherogenic Index of Plasma in Axial Spondyloarthritis: Two-year Follow-up Data from the Catholic Axial Spondyloarthritis COhort (CASCO)
Abstract Number: 1341

Impact of Tocilizumab on Anxiety and Depression in Patients with Rheumatoid Arthritis
Abstract Number: 1348

Impact of Tofacitinib on the Individual Components of the ACR Composite Score in Patients with Rheumatoid Arthritis: A Post Hoc Analysis of Phase 3 Trials
Abstract Number: 1658

Impact of Visceral Involvement in the Characterization and Prognosis of Patients Without Skin Involvement Classified as Systemic Sclerosis (SSc) According to 2013 ACR/EULAR Criteria in a Large Single Cohort
Abstract Number: 1406

Impact on Costs and Quality of Life over 5 Years of Treat-to-target Treatment Strategies Initiating Tocilizumab, Methotrexate or Their Combination in Early Rheumatoid Arthritis: Economic Evaluation of the U-Act-Early Trial
Abstract Number: 2720

Implementation of an Evidence-based Transition Clinic in a Pediatric Rheumatology Academic Institution
Abstract Number: 316

Implementation of Cardiovascular Screening in Hispanic Patient Population with RA, SLE and PsA
Abstract Number: 151

Implementation of Recommendations for Prevention of Glucocorticosteroid-Induced Osteoporosis in Hospitalized Patients
Abstract Number: 834

Implementing Patient-Reported Outcome Measures in Clinical Care: Rheumatologist Perspectives on Opportunities and Challenges
Abstract Number: 2828

Implementing the BP Connect Systems-Based Blood Pressure Follow-Up Protocol with Community Rheumatology Clinic Teams
Abstract Number: 2473

Implementing the Psoriatic Arthritis Disease Activity Score (PASDAS) in Routine Clinical Practice: (im)possible?
Abstract Number: 2767

Importance of Discussing RA Treatment Goals: Patients Report Providers Seldom Discuss Treatment Goals and Outcomes Improve When Goals Are Discussed
Abstract Number: 2538

Importance of Serum Phosphatidylserine-Specific Phospholipase A1 (PS-PLA1) as a Novel Disease Activity Biomarker of Systemic Lupus Erythematous
Abstract Number: 984

Important Role of CD11c+ Cells in Inflammatory Arthritis
Abstract Number: 2314

Improved Anxiety, Depression, and Emotional Distress for Rheumatoid Arthritis Patients Following the Completion of an Online Mental Health Intervention

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].